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Abstract 
Fetal growth restriction (FGR) in pregnancy is commonly caused by impaired uteroplacental blood 
flow. Vasodilators enhance uteroplacental perfusion and fetal growth in humans and animal 
models; however, detrimental maternal and fetal side effects have been reported. We 
hypothesised that targeted uteroplacental delivery of a vasodilator would enhance drug efficacy 
and reduce the risks associated with drug administration in pregnancy. Phage screening identified 
novel peptides that selectively accumulated in the uteroplacental vasculature of pregnant mice. 
Following intravenous injection, the synthetic peptide CNKGLRNK selectively bound to the 
endothelium of the uterine spiral arteries and placental labyrinth in vivo; CNKGLRNK-decorated 
liposomes also selectively bound to these regions. The nitric oxide donor 
2-[[4-[(nitrooxy)methyl]benzoyl]thio]-benzoic acid methyl ester (SE175) induced significant 
relaxation of mouse uterine arteries and human placental arteries in vitro; thus, SE175 was 
encapsulated into these targeted liposomes and administered to healthy pregnant C57BL/6J mice 
or endothelial nitric oxide synthase knockout (eNOS-/-) mice, which exhibit impaired 
uteroplacental blood flow and FGR. Liposomes containing SE175 (0.44mg/kg) or PBS were 
administered on embryonic (E) days 11.5, 13.5, 15.5 and 17.5; fetal and placental weights were 
recorded at term and compared to mice injected with free PBS or SE175. Targeted uteroplacental 
delivery of SE175 had no effect on fetal weight in C57BL/6J mice, but significantly increased fetal 
weight and mean spiral artery diameter, and decreased placental weight, indicative of improved 
placental efficiency, in eNOS-/- mice; free SE175 had no effect on fetal weight or spiral artery 
diameter. Targeted, but not free SE175 also significantly reduced placental expression of 
4-hydroxynonenal, cyclooxygenase-1 and cyclooxygenase-2, indicating a reduction in placental 
oxidative stress. These data suggest that exploiting vascular targeting peptides to selectively deliver 
SE175 to the uteroplacental vasculature may represent a novel treatment for FGR resulting from 
impaired uteroplacental perfusion. 
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Introduction 
More than five percent of pregnancies are 
complicated by fetal growth restriction (FGR), where 
the developing fetus does not reach its full growth 
potential, resulting in significant maternal and fetal 
morbidity and/or mortality [1,2]. There is also 
evidence that being born small or premature can 
program obesity and increase the risk of adulthood 
diseases such as cardiovascular disease and type 2 
diabetes [3]. Current management strategies are 
limited to fetal monitoring, and induction of labour 
when suboptimal growth threatens fetal survival [4]. 
However, pre-term delivery can exacerbate some of 
the adverse effects associated with growth restriction 
[5]. Despite these short and long-term health 
implications, development of therapeutics for use in 
pregnancy is hindered by the risk of systemic side 
effects and lack of interest from the pharmaceutical 
industry [6,7]. 
Peptide-mediated targeting of payloads to 
individual vascular beds has enabled selective 
delivery of therapeutics to specific organs and tissues 
[8,9], offering enhanced efficacy and importantly, 
reducing off-target, systemic side effects [10]. Much of 
the current research in this area has focussed on 
delivery of chemotherapeutics to tumours, which has 
been achieved by targeting specific receptors on the 
tumour vasculature [11, 12]. A peptide that homes to 
atherosclerotic plaques has also been identified, 
which triggers apoptosis of plaque macrophages and 
reduces plaque hypoxia [13,14]. The villous placenta 
and surrounding uterine vasculature express a 
number of cell-surface epitopes common to those 
observed in the vasculature in solid tumours [15]. 
Indeed, the placenta has been likened to a solid 
tumour, exhibiting high rates of proliferation in the 
first trimester, giving rise to a subset of invasive cells 
and modulating the maternal immune response. 
These observations, along with our finding that some 
peptides which home to tumours can also be 
exploited for placental targeting [16], led us to seek 
novel sequences that home to the uteroplacental 
vasculature.  
Abnormal vascular anatomy [17] and impaired 
myometrial and chorionic plate vascular tone 
regulation are present in some cases of FGR in 
humans [18-22]. Reduced uterine and umbilical blood 
flow alters the diffusion gradient for transfer of small 
lipophilic solutes such as O2 and CO2 across the 
placenta [23], thus restricting fetal growth. Moreover, 
impaired uteroplacental blood flow contributes to 
FGR in both human and mouse pregnancies [24,25], 
suggesting that enhancement of flow may provide a 
means to improve fetal growth in utero. Indeed, 
administration of the vasodilator sildenafil citrate 
(Viagra™) to pregnant women presenting with FGR 
improved uteroplacental perfusion, as identified by 
Doppler ultrasound [26]. Sildenafil citrate also 
significantly increased fetal weight in the two mouse 
models of FGR [27-29]; however, maternal 
administration of sildenafil citrate caused impaired 
vasorelaxation of fetal abdominal aortas, led to female 
offspring exhibiting impaired glucose tolerance, and 
caused the offspring to have elevated blood pressure 
as adults [27,30,31]. These studies demonstrate the 
potential side effects of systemic maternal delivery of 
therapeutics in pregnancy and lend support to the use 
of targeted drug delivery. 
In this study, we have used phage screening to 
identify novel peptide sequences that selectively bind 
to the uteroplacental vasculature and created 
liposomes bearing one such sequence for targeted 
drug delivery. We have also assessed the ability of a 
novel vasodilator, 2-[[4-[(nitrooxy)methyl]benzoyl]-
thio]-benzoic acid methyl ester (SE175), to relax 
uterine arteries from pregnant mice and enhance fetal 
growth in vivo. SE175, a nitroxyacylated thiosalicylate, 
contains a nitric oxide (NO)-donating nitrate group 
attached to a NO-liberating thiosalicylate [55]; this 
class of compound was created in an effort to achieve 
spontaneous release of NO from nitrate groups, based 
on the evidence that a free thiol (SH) is able to liberate 
NO from nitrate groups [72]. Esterase breakdown of 
SE175 allows the thiosalicylate group to self-liberate 
NO from the nitrate group, thus SE175 should not 
cause the tolerance that has been observed following 
repeated administration of traditional nitrates. 
We evaluated the effects of SE175 in pregnant 
wild-type C57BL/6J mice and in endothelial nitric 
oxide synthase (eNOS-/-) knockout mice, which 
exhibit pre-pregnancy hypertension and a 
compromised adaptive cardiovascular response to 
pregnancy: uterine artery remodeling is impaired 
[32,33] and uteroplacental perfusion is reduced [34]. 
Offspring are on average 10% lighter than in 
C57BL/6J mice indicating FGR [35]. No gross 
structural abnormalities have been reported in 
eNOS-/- mice but placental nutrient transport is 
reduced, and placentas exhibit evidence of oxidative 
stress and uteroplacental hypoxia [36]. Oxidative 
stress in the mouse placenta leads to the induction of 
both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 
(COX-2), leading to prostaglandin synthesis and 
elevated rates of apoptosis [37]. Here we demonstrate 
that targeted delivery of SE175 to the uteroplacental 
vasculature of eNOS-/- mice enhances fetal growth 
and reduces placental oxidative stress.  
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Methods 
Animal procedures  
BALB/c mice (Charles River, USA), C57BL/6J 
mice (UK) and eNOS mice (UK) were housed and all 
procedures were performed according to procedures 
approved by the Animal Research Committees at 
University of California, Santa Barbara, or in 
accordance with the UK Animals (Scientific 
Procedures) Act 1986 at The University of 
Manchester. Animals had free access to food and 
water and were maintained on a 12:12 h light–dark 
cycle at 21–23°C. After mating, the presence of a 
copulation plug was denoted as embryonic day 0.5 
(E0.5) of pregnancy. 
Phage display 
The T7-select phage display system (EMD 
Biosciences, USA) was used to construct peptide 
libraries. Individual phages were cloned according 
the manufacturer’s instructions, as previously 
described [38,39]. Amplified phages were purified 
from bacterial lysate by precipitation with PEG-8000 
(Sigma Aldrich, MO, USA), caesium chloride gradient 
ultracentrifugation and dialysis. The identity of the 
displayed peptides was determined by sequencing 
the DNA encoding the insert-containing region at the 
C terminus of the T7 major coat protein gp10 (Eton 
Bioscience, CA, USA).  
Phage screening 
Mouse placentas (E13.5 - E14.5) were harvested, 
washed in PBS and mechanically dissociated using a 
Medimachine system (BD Biosciences). The resulting 
tissue aggregates were incubated with the T7 phage 
library (1010 pfu/mg tissue) in 10 ml DMEM culture 
medium containing 1% (w/v) BSA (Life Technologies, 
NY, USA) for 1 h at 4°C on a rotating wheel, then 
pelleted by centrifugation (400g; 5 min). Tissue was 
washed by centrifugation (400 g; 5 X 5 min) in fresh 
culture medium and lysed in LB bacterial growth 
medium containing 1% Nonidet P-40 (Sigma Aldrich, 
MO, USA). Bound phage was quantified by titration 
and amplified as previously described [38,39]. The ex 
vivo selection process was repeated three times, then 
the resulting phage pool was injected into the tail vein 
of a pregnant mouse and allowed to circulate for 30 
min. To remove unbound phage, mice were subjected 
to terminal cardiac perfusion with 30 ml of PBS. The 
uterus and placentas were harvested and 
homogenized in LB bacterial growth medium 
containing 1% (v/v) Nonidet P-40, and bound phage 
were titered, amplified and purified. Four rounds of 
in vivo screening were performed in total, using 
pregnant mice between E13.5 and E15.5. Ninety-six 
individual phage clones from each of the second, third 
and fourth rounds of screening were subjected to 
DNA sequencing to determine the identity of their 
surface peptides.  
Peptide synthesis 
Peptides were synthesized at The University of 
California, Santa Barbara using Fmoc chemistry in a 
solid–phase synthesizer, were purified by HPLC, and 
sequences and structures confirmed by mass 
spectrometry as previously described [38]. 
Alternatively, they were purchased from Insight 
Biotechnology, UK.  
Peptide targeting 
Individual synthetic peptides (200 µg) labeled 
with 5(6)–carboxyfluorescein (FAM) were injected 
into the tail vein of pregnant mice (E11.5–E17.5) and 
allowed to circulate for 3 h. Following terminal 
cardiac perfusion with PBS to remove unbound 
peptide, maternal and fetal tissues were collected for 
analysis. Organs were snap frozen, or fixed in 
paraformaldehyde (4% (w/v) in PBS; overnight) and 
cryoprotected in sucrose solution (30% (w/v) in PBS; 
24 h), embedded in OCT (Sakura) and stored at –80 
°C. Tissue sections (8 μm) were fixed in ice–cold 
methanol (15 min), washed in PBS (2 X 5 min), 
mounted in Vectashield medium containing DAPI 
(4′,6–diamidino–2–phenylindole; Vector Laboratories, 
Burlingame, USA) and examined on an Olympus 
Fluoview 500 confocal microscope (Olympus 
America) or a Zeiss AxioObserver fluorescence 
microscope (Zeiss, UK). Images were captured at the 
same exposure so that comparisons of fluorescence 
intensity could be made between samples.  
Liposome synthesis 
Targeted liposomes were prepared by dissolving 
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC; 65 
μmol/L), cholesterol (30 μmol/L), 1,2-distearoyl- 
sn-glycero-3-phosphoethanolamine-N-[amino(polyet
hylene glycol)] (DSPE-PEG; 4.5 μmol/L) and 
DSPE-PEG-maleimide (0.5 μmol/L; Avanti Polar 
Lipids) in methanol:chloroform (9:1 ratio). Solvent 
was removed by rotary evaporation to produce a thin 
lipid film, which was rehydrated with distilled water 
(2 mL). The resulting suspension was heated to 62oC 
for 3 h to produce large multilamellar vesicles and 
extruded eleven times using a 1 mL Mini-Extruder 
(Avanti Polar Lipids) through a 0.1 μm, 19 mm 
polycarbonate membrane, surrounded by two 10 mm 
filter supports in order to produce a unilamellar 
liposome suspension. Fluorescent targeting peptides 
(0.27 μmol/L) bearing a cysteine residue on the 
N-terminus were added to 1 mL of extruded liposome 
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suspension and allowed to covalently couple with 
maleimide groups overnight at room temperature via 
a Michael type addition reaction. Unreacted peptide 
was removed by dialysis against PBS (8 X 1 litres; 24 h; 
Slide-A-Lyzer Dialysis Cassettes, MWCO 3.5 kDa) 
and the suspension stored at 4oC until use. The size 
(hydrodynamic diameter) distribution (SD) and 
polydispersity index (PDI) were measured by 
dynamic light scattering (DLS), and the zeta potential 
(ZP) was measured by laser Doppler 
micro-electrophoresis (LDE) (25oC; scattering angle of 
173o (Zetasizer Nano ZS, Model ZEN3600, fitted with 
a 632 nm laser, Malvern Instruments Ltd., UK). 
To encapsulate SE175, the lipid film was 
rehydrated with SE175 (2 mL, 320 µmol/L stock) and 
the resultant suspension was heated at 62oC for 3 h 
and extruded, as described above. Fluorescent 
targeting peptides (0.27 μmol/L) were conjugated to 
maleimide groups on the liposomal surface via a 
Michael–type addition reaction. Unreacted peptide 
was removed by dialysis against PBS and the 
suspension was stored at 4oC. 
Non-targeted liposomes were prepared by 
dissolving DPSC (65 μmol/L), cholesterol (30 
μmol/L), DSPE-PEG (5 μmol/L) in 
methanol:chloroform (9:1 ratio), followed by the 
addition of 2.7 μmol/L of fluorescently labelled lipid 
NBD-DSPE (5 0μL, 0.1 mg/mL stock). As described 
above, the solvent was removed by rotary 
evaporation, the lipid film was rehydrated with PBS 
(2 mL) and the resultant suspension was heated at 
62oC for 3 h. The suspension was then extruded using 
a 1 mL Mini-Extruder through a 0.1 μm, 19 mm 
polycarbonate membrane, free drug was removed by 
dialysis against PBS and the suspension was stored at 
4oC. 
Validation of liposome targeting in vivo 
Liposomes (100 µL) decorated with 
rhodamine-labelled CNKGLRNK peptides and 
NBD-labelled fluorescent lipids were injected into the 
tail vein of pregnant mice (E13.5–E15.5) and allowed 
to circulate for up to 48h. Following terminal cardiac 
perfusion with PBS to remove unbound liposomes, 
maternal and fetal tissues were collected for analysis. 
Organs were fixed in neutral buffered formalin (4% 
(v/v); overnight), embedded in OCT (RA Lamb, UK) 
and stored at –80 °C. Tissues sections (8 μm) were 
fixed in PFA (15 min), washed in PBS (2 X 5 min), 
mounted in Vectashield mounting medium 
containing DAPI and examined using a Zeiss 
AxioObserver fluorescence microscope (Zeiss, UK). 
Images were captured at the same exposure so that 
comparisons of fluorescence intensity could be made 
between samples.  
Human tissue 
First trimester placentas were collected 
following surgical or medical termination of 
pregnancy. Term placentas (37–42 weeks gestation) 
were obtained from normal pregnancies within 30 
min of vaginal or Caesarean delivery. The study was 
performed in accordance with North West Local 
Research Ethical Committee approvals (08/H1010/28; 
08/H1010/55) and written informed consent was 
obtained from all patients. Villous tissue was 
randomly sampled, washed in serum–free culture 
medium and dissected into 3 mm3 explants under 
sterile conditions. Explants were cultured a 1:1 ratio of 
DMEM and Ham’s F12 media (Lonza Biosciences, 
UK) containing glutamine (2 mmol/L), penicillin (100 
IU ml-1), streptomycin (100 µg ml-1) and 10% (v/v) 
fetal bovine serum (Life Technologies), in 24 well 
culture plates pre–coated with agarose (1% (w/v); 
Sigma Aldrich). Explants were maintained in 20% O2, 
5% CO2 at 37 °C for up to 7 days. 
Peptide binding to human placental explants  
Rhodamine–labelled peptides (20 µmol/L) were 
incubated with human first trimester or term 
placental explants at 37°C for up to 3 h in culture 
media. Tissue was washed in PBS, fixed in neutral 
buffered formalin overnight (4% (v/v); pH 7.4), 
frozen and cryosectioned. Tissues sections (8 μm) 
were fixed in PFA (15 min), washed in PBS (2 X 5 
min), mounted in Vectashield mounting medium 
containing DAPI and assessed using a Zeiss 
AxioObserver fluorescence microscope. 
Liposome binding to human placental explants  
Peptide-decorated liposomes (100 µL) were 
cultured with term placental explants (37oC, 95% air, 
5% carbon dioxide) for up to 48 h. Tissue was washed 
in PBS, fixed in neutral buffered formalin overnight 
(4% (v/v); pH 7.4), frozen and cryosectioned. Tissue 
sections (8 μm) were fixed in PFA (15 min) and 
washed in PBS (2 X 5 min). Sections were mounted in 
Vectashield containing DAPI and visualised using a 
Zeiss AxioObserver fluorescence microscope.  
Wire myography 
Pregnant female mice were euthanized by 
cervical dislocation at E18.5. A surgical laparotomy 
was performed on the dam to expose the uterine horn. 
The horn was pinned out as previously described [36] 
and main loop uterine artery carefully excised using a 
dissection microscope (model S6E, Leica, UK). The 
dissected artery was trimmed into approximately 40 
µm length sections and kept in cold physiological salt 
solution prior to mounting on the wire myograph. 
Dissected arterial sections were mounted by inserting 
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two 40 µm steel wires into the lumen, which were 
secured in the jaws of a Multi Myograph System 610M 
(Danish Myo Technology A/S, Denmark) as 
previously described [40]. Arterial section diameter 
was measured using a calibrated eyepiece graticule 
and equilibrated to physiological conditions in 6 mL 
PSS, warmed to 37oC and gassed with 20% O2 / 5% 
CO2 / balanced with N2 (BOC Gases, Worsley, UK). 
Vessels were normalised to ensure that arterial 
sections of different diameters had the same resting 
tension, as previously described [41], and were left to 
equilibrate for 20 minutes.  
Chorionic plate biopsies taken from human term 
placentas were placed into ice-cold PSS. Small 
chorionic plate arterial branches originating from the 
main umbilical arteries were identified, dissected and 
trimmed into approximately 40 µm length sections. 
Vessels were mounted on a wire myograph and 
normalised as described above.  
Human chorionic plate and mouse uterine 
arteries were exposed to a high potassium salt 
solution for 5 min to determine maximal smooth 
muscle contraction, before being washed twice with 
PSS. Arterial sections were left to re-equilibrate for 20 
min, before being exposed to phenylephrine (PE, 10-5 
mol/L) for 10 min to determine maximal contraction. 
After 10 min, arterial sections were exposed to 
acetylcholine (ACh, 10-5 mol/L) to determine maximal 
relaxation, before being washed twice with PSS and 
left to equilibrate for 20 min. PE exposure was then 
repeated and relaxation to SE175 determined, 
following the application of incremental doses (10-9 – 
10-5 M, 2 min intervals). Equivalent concentrations of 
DMSO (vehicle control) and no treatment (time 
control) were assessed in parallel. When targeted 
liposomes containing SE175-were applied to arterial 
sections, the extent of relaxation to a single dose (100 
µl) of SE175 was determined. Relaxation data were 
expressed as percentage relaxation of maximum 
pre-constriction to PE. Myodata software (version 
2.02; Myonic Software, National Instruments 
Corporation, USA) was used to visualise and interpret 
data. 
Measurement of system A activity 
After 6 days in culture, term placental explants 
were treated with SE175 (10 µM), SNAP (10 µM) or 
DMSO (0.6 %; vehicle control) and system A activity 
was measured on day 7. Explants were incubated for 
30, 60 or 90 min in either Na+-containing or Na+-free 
Tyrode's buffer (NaCl replaced by an equimolar 
concentration of choline chloride) containing 
0.5 μCi/ml 14C-MeAIB (∼8.5 μM) at 37 °C. The 
explants were then washed in ice-cold Tyrode’s buffer 
and lysed in dH2O for 16–18 h at room temperature 
(RT). The radioactive content of the water lysate was 
measured using a β-counter. Na+-dependent system A 
activity was calculated by subtracting uptake in 
Na+-free Tyrode's from that in Na+-containing 
Tyrode's, with correction for fragment protein 
content, measured using Bio-Rad protein assay 
(Bio-Rad Laboratories Ltd, Hertfordshire, UK). 
Liposome treatment study 
Time-mated, pregnant C57 and eNOS-/- mice 
were intravenously injected with 100 µL of either PBS, 
CNKGLRNK-decorated liposomes containing PBS, 
free SE175 (320 µmol/L, approximately 0.44 mg/kg) 
or CNKGLRNK-decorated liposomes containing 
SE175 (320 µmol/L; approximately 0.44 mg/kg) on 
E11.5, E13.5, E15.5 and E17.5. Mice were sacrificed by 
cervical dislocation at E18.5 and the following 
measurements taken: litter size, number of 
resorptions, fetal weight, placental weight, maternal 
kidney weight, maternal spleen weight and maternal 
heart weight. Organs were fixed in neutral buffered 
formalin (4% (v/v), pH 7.4; overnight) for paraffin 
embedding. The weight and behaviour of treated 
dams were continuously monitored to detect signs of 
toxicity or distress. Gross morphological analysis of 
fetuses and maternal organs was undertaken to detect 
physical deformities or abnormalities associated with 
treatment. 
Immunostaining 
Tissue sections (5 µm) were deparaffinised in 
Histoclear and alcohol and then rehydrated in dH2O. 
Slides were microwaved in antigen retrieval buffer 
(sodium citrate buffer (0.01 mol/L), containing 0.05% 
(v/v) Tween 20 (pH 6.0), 20 min), followed by cooling 
for 10 min. After cooling, tissue sections were 
incubated with hydrogen peroxidase (3% (w/v), 10 
min) to block endogenous peroxide activity, washed 3 
times in Tris-buffered saline (TBS) and incubated with 
bovine serum albumin (BSA; 5% (w/v) in TBS, 30 
min) to block non-specific binding. Tissue sections 
were then incubated with primary antibodies (Table 
1) or control IgG (matched concentration; Sigma 
Aldrich) overnight at 4oC. Tissue sections were 
washed 3 times (TBS; 5 min) and incubated at room 
temperature with a swine anti-rabbit or goat 
anti-mouse secondary antibody (1:200; 
DakoCytomation A/S) for 30 min. Tissue sections 
were then washed 3 times (TBS; 5 min) and incubated 
at room temperature with avidin peroxidase (5 
µg/mL in TBS, 30 min; Sigma Aldrich). Tissue 
sections were then washed with dH2O, incubated for 
2-10 min with diaminobenzidine (DAB; 0.05% (w/v); 
Sigma Aldrich) and urea hydrogen peroxide (0.015% 
(v/v); Sigma Aldrich, UK) and washed again with 
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dH2O. Tissue sections were then counterstained with 
filtered Harris's hematoxylin, dehydrated in alcohol 
and Histoclear and mounted in DPX mountant (Sigma 
Aldrich, UK). All sections were stained in the same 
run to allow direct comparison between groups. 
Table 1. Primary antibodies 
Antigen Host Species Target 
Species 
Supplier  Dilution 
COX-1 
aa 274 – 288 
#160109  
Rabbit  Mouse Cayman Chemicals, 
UK 
1:250 
COX-2 
aa 584 – 598 
#160126 
Rabbit  Mouse Cayman Chemicals, 
UK 
1:1000 
HNE 
#HNE11-S 
Rabbit  Mouse Alpha Diagnostics, UK 1:500 
Ki67 (clone 
MIB-1) 
Mouse Human DakoCytomation A/S, 
Denmark  
1:250 
M30 
CytoDEATH 
Mouse Human Roche Diagnostics 
GmbH, UK 
1:100 
IgG 
#I8140 
Rabbit Mouse Sigma Aldrich, UK Matched 
IgG 
#I8765 
Mouse Human Sigma Aldrich, UK Matched 
 
For quantitative analysis of immunostaining, a 
minimum of three treated mice per group were 
selected at random and three placentas per mouse 
were immunostained in the same run for direct 
comparison of images. Nine images were taken per 
placenta using the same exposure settings, on the 
Olympus B641 Light Microscope using Image-Pro 
Plus 7 software, equating to twenty-seven images per 
mouse (taken as n = 1). Images were then analysed 
using TissueGnostics HistoQuest® Analysis Software. 
Hematoxylin (nuclear stain) total area and DAB 
(antibody stain) total area were determined and a 
ratio of DAB area to hematoxylin area calculated to 
control for tissue area. The mean luminal diameter of 
individual spiral arteries was also quantified using 
HistoQuest® software. For human tissue, six random 
images were taken of each explant using the same 
exposure settings and analysed using the HistoQuest 
software. The percent of proliferating and apoptotic 
cells was calculated by dividing the total area of 
DAB-positive nuclei (Ki67 or M30 positive cells) by 
the total area of haematoxylin-positive nuclei and 
multiplying by 100. 
 Statistical analysis 
All data were analysed using GraphPad Prism 
software (Version 7). Myography data were analysed 
using two-way analysis of variance with Bonferroni 
post hoc test for comparisons between groups. System 
A activity was analysed using linear regression to 
assess differences in the rate of Na+-dependent 
14C-MeAIB uptake between treatments. Unless 
otherwise stated, all other data were analysed using 
one-way ANOVA or a Kruskal Wallis test with 
Dunnett post hoc test for comparisons between groups. 
Frequency distribution curves were generated by 
performing non-linear regression on fetal / placental 
weight histograms. Unless otherwise stated, data are 
shown as mean ± SEM and significance was taken as 
P < 0.05. 
Results 
The placental-homing peptide NKGLRNK 
selectively binds to the uteroplacental 
vasculature 
To isolate placental homing phages, mouse 
placental tissue (E13.5-14.5) was incubated with a T7 
bacteriophage library containing about 108 individual 
clones, in which each clone displays multiple copies of 
a unique, random 7-mer peptide on its surface. Each 
sequence is represented ~100 times, thus the starting 
library contained approximately 1010 phage. During 
the three rounds of ex vivo phage selection, the phage 
library collapsed by three orders of magnitude (107 to 
104; Figure 1A), as previously reported [39]; however, 
subsequent rounds of in vivo screening led to phage 
enrichment (Figure 1B). Ninety-six phage clones from 
the second, third and fourth rounds of in vivo 
screening were sequenced and the surface peptide 
NKGLRNK (NKG) was the most highly represented. 
To confirm that this sequence selectively targets the 
mouse placenta in vivo, synthetic peptide labelled 
with 5(6)–carboxyfluorescein (FAM) was injected 
intravenously into pregnant mice. FAM-NKG bound 
to the intima of decidual spiral arteries (SA) and the 
vasculature of the placental labyrinth (Lab), but not to 
the junctional zone (JZ) between E10.5 and E17.5 
(Figure 1C-E). Analysis of maternal tissues confirmed 
that FAM-NKG did not accumulate in the vascular 
bed of any other major organ, although small, discrete 
areas of fluorescence were sometimes observed in the 
kidney and spleen (Figure 1F-K).  
Homing peptide-decorated liposomes 
preferentially home to the uteroplacental 
vasculature 
To conjugate the homing peptide to the surface 
of liposomes it was necessary to add a cysteine 
residue to the N-terminus: CNKGLRNK (CNKG). To 
ensure that tissue binding was not affected, excised 
mouse uterine arteries were incubated with 
rhodamine (Rh)-labelled peptide (20 µmol/L) for up 
to 3 h. Rh-CNKG bound to, and accumulated within, 
the vascular endothelium and underlying smooth 
muscle layers (Figure 2A, B), as observed in vivo. 
Rh-CNKG-coupled liposomes containing PBS or 
SE175 were synthesised and characterised; 
PBS-loaded liposomes had a mean diameter of 159.8 ± 
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1 nm, a mean zeta potential of -0.6 ± 0.4 mV and a 
polydispersity index of 0.065. SE175-loaded liposomes 
had a diameter of 164.2 ± 1 nm, a zeta potential of -1.0 
± 0.6 mV and a polydispersity index of 0.049 (Figure 
2C, D). The liposomes demonstrated excellent 
stability over 28 days, with mean particle size and 
polydispersity index remaining constant during this 
time.  
 
 
Figure 1. Identification of the placental-homing peptide NKGLRNK [A] Mouse placental tissue was incubated with a T7 bacteriophage library and bound 
phages were titered, amplified and purified. Phage titer (pfu/mg tissue) was measured using a plaque-forming assay (n=3). [B] Following 3 rounds of ex vivo selection, 
the resulting phage pool was injected into the tail vein of a pregnant mouse. Placentas were harvested and bound phage pools were titered, amplified and purified. Four 
rounds of in vivo screening were performed in total; phage titer is expressed as pfu/mg tissue (n = 3). [C-E] NKGLRNK labelled with 5(6)-carboxyfluorescein (FAM; 
200 μg) was injected into the tail vein of pregnant mice (n = 5; E10.5 - E17.5). Following cardiac perfusion to remove unbound peptide, placentas were harvested and 
assessed by fluorescence microscopy. Representative images are shown. FAM-labelled peptides, green; DAPI (nuclei), blue. JZ = junctional zone; Lab = labyrinth; SA 
= spiral artery.  
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Figure 2. CNKGLRNK binding to uteroplacental tissue in vitro and in vivo [A, B] Segments of mouse uterine artery were incubated with Rh-CNKGLRNK (0.27 
µmol/L; red) for up to 3 h. Peptide binding and uptake was assessed by fluorescence microscopy (n = 3). Representative images are shown. Rh-labelled peptides, red; DAPI 
(nuclei), blue. ED = endothelium; LU = lumen. Scale bar = 50 µm. [C] Size distribution of freshly prepared Rh-CNKGLRNK-decorated liposomes containing either PBS (blue) or 
SE175 (red). A representative plot from n = 3 liposome preparations is shown. [D] Size distribution of Rh-CNKGLRNK–decorated liposomes containing PBS over a 28 day 
period (n=3). Representative plots from one preparation are shown. [E – H] Placentas from pregnant C57BL/6J mice collected at E18.5, following tail vein injection of 
Rh-CNKGLRNK (red)-decorated liposomes composed of NBD-labelled lipids (green), 6h, 24h or 48h prior to tissue harvest. Cardiac perfusion was performed to remove 
unbound peptide; organs were removed and assessed by fluorescence microscopy. Yellow, co-localisation of peptide (red) and lipid (green) fluorescence. Blue, DAPI (nuclei). SA, 
spiral artery; LB, labyrinth. Scale bars = 50 µm. n = 3 placentas from n = 3 mice per treatment group were examined. Representative images are shown.  
 
To validate liposome targeting in vivo, 
Rh-CNKG-coupled liposomes prepared using 
fluorescent NBD lipids (green) were injected 
intravenously into pregnant mice at E15.5 and 
allowed to circulate for 6 h, 24 h or 48 h. 
Colocalisation of peptide and lipid fluorescence was 
observed in the placental labyrinth and the decidual 
spiral arteries (Figure 2E-H), with a pattern of 
localisation similar to free NKG peptide. Fluorescence 
was not observed in the maternal heart, lungs, brain 
or in any fetal tissues; however a transient signal was 
seen in the maternal liver, kidney and spleen 
(Supplementary Figure 1), in line with previous 
reports of non-specific uptake of nanoparticles by the 
clearance organs [42]. 
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The nitroxyacylated thiosalicylate SE175 
induces dilation of uteroplacental arteries in 
mice and humans  
Free SE175 was applied in increasing 
concentrations to freshly isolated uterine arteries from 
C57BL/6J and eNOS-/- mice, or human chorionic plate 
arteries from healthy term placentas, pre-constricted 
with phenylephrine. SE175 induced a significant, 
dose-dependent relaxation of C57BL/6J and chorionic 
plate vessels (Figure 3A, B), compared to untreated 
arteries and arteries treated with vehicle control; at a 
concentration of 10-5 M, SE175 induced a significant 
time-dependent relaxation of eNOS-/- uterine arteries 
(Figure 3C). Similarly, when encapsulated in 
CNKG-decorated liposomes, 10-5 M SE175 induced a 
significant, time-dependent relaxation of C57BL/6J 
and chorionic plate arteries, compared to untreated 
vessels and those treated with the vehicle control 
(Figure 3D, E).  
 
 
Figure 3. Human and mouse vessels relax in response to SE175 ex vivo [A, D] C57BL/6J mouse uterine arteries, [B, E] human term placental chorionic 
plate arteries, and [C] eNOS-/- mouse uterine arteries were collected, the arteries dissected and mounted onto a wire myograph. Vessels were pre-constricted with 
phenylephrine and vessel relaxation to [A - C] free or [D, E] liposomally-encapsulated SE175 was recorded. [A, B] Dose-dependent relaxation; [C-E] 
time-dependent relaxation to 10-5 M SE175. SE175 (black circles, n = 6), DMSO (blue squares, n = 6), time control (no treatment; red triangles, n = 6). Mean ± SEM; 
error bars not visible if smaller than symbol. Dose response curves were compared using two-way ANOVA with Bonferroni’s post hoc test. **P<0.001, ***P<0.0008, 
****P<0.0001. 
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Targeted delivery of SE175 increases fetal 
weight, placental efficiency and decidual spiral 
artery diameter in eNOS-/- mice 
To determine whether SE175 could increase fetal 
growth by enhancing uteroplacental blood flow, 
pregnant wild-type C57BL/6J mice were 
intravenously injected with PBS, PBS-loaded 
CNKG-decorated liposomes, SE175-loaded 
CNKG-decorated liposomes or free SE175 on E11.5, 
E13.5, E15.5 and E17.5 of pregnancy. Whilst the 
treatments were well tolerated and did not 
significantly alter litter size or proportion of 
resorptions, targeted delivery of SE175 to the 
uteroplacental vasculature did not significantly alter 
fetal or placental weights, and administration of free 
SE175 modestly but significantly decreased fetal 
weight (Supplementary Figure 2). In contrast, when 
administered to eNOS-/- mice, a model of 
pre-pregnancy hypertension and FGR, targeted SE175 
increased fetal weight (Figure 4A); no other treatment 
had a significant effect. Fetuses from eNOS-/- mice 
had a mean weight 13 % lower than that of C57BL/6J 
mice; targeted delivery of SE175 increased mean fetal 
weight by 4 % compared to PBS-treated eNOS-/- mice. 
After targeted SE175 treatment no fetuses fell below 
the 5th or 10th weight centiles, thresholds that are 
commonly used clinically to define FGR (Figure 4B). 
Importantly, fewer fetuses with the lowest weights 
were observed in the treatment group, whereas the 
number of fetuses of appropriate weight was not 
changed (Figure 4A). In addition, no treatment 
significantly altered litter size or the resorption rate 
(Supplementary Figure 3). This suggests that targeted 
delivery of SE175 increases the weight of the smallest 
fetuses, without causing detrimental overgrowth of 
the heavier fetuses. 
eNOS-/- placentas were on average 6 % heavier 
than those of healthy C57BL/6J; targeted delivery of 
SE175 significantly reduced placental weight by an 
average of 9 %, compared to PBS-treated eNOS-/- mice 
(Figure 4C). Placental efficiency, described in terms of 
the fetal:placental weight ratio, was on average 18 % 
lower in PBS-treated eNOS-/- mice than in PBS-treated 
C57BL/6J mice; targeted delivery of SE175 
significantly increased F:P weight ratio in eNOS-/- 
mice by an average of 15 % compared to PBS 
treatment (Figure 4D). Delivery of free SE175 also 
significantly decreased placental weight and 
enhanced fetal:placental weight ratio compared to 
controls, but this improvement in placental efficiency 
did not translate into increased fetal weights.  
Maternal blood is supplied to the placenta via 
the decidual spiral arteries. Quantification of mean 
arterial diameter revealed that eNOS-/- arteries were 
on average 28 % narrower than those of C57BL/6J; 
targeted delivery of SE175 significantly increased 
spiral artery diameter by an average of 33 % 
compared to PBS-treated eNOS-/- mice, and 17 % 
compared to PBS liposome-treated eNOS-/- mice 
(Figure 4E). Systemically administered SE175 had no 
significant effect on mean arterial diameter. All of the 
observed effects were independent of fetal sex. 
Targeted delivery of SE175 significantly 
reduces placental oxidative stress  
Placentas from treated eNOS-/- mice were 
immunostained for the lipid peroxidation product 
4-hydroxynonenal (4-HNE), as a marker of oxidative 
stress; PBS-treated C57BL/6J mice were also included 
for comparison. HNE immunoreactivity was 
observed throughout the decidua, junctional zone and 
labyrinth of vehicle treated eNOS-/- mouse placentas. 
The area of immunopositive tissue was quantified and 
expressed as a ratio of the total tissue area; targeted 
delivery of SE175 significantly reduced the area of 
placental 4-HNE immunostaining, suggestive of a 
reduction in lipid peroxidation in eNOS-/- mice 
(Figure 5A). No significant differences were observed 
in any other treatment groups. Placentas were also 
immunostained for COX-1 and COX-2; 
immunoreactivity was observed throughout the 
decidua, junctional zone and labyrinth of eNOS-/- 
placentas. Targeted delivery of SE175 also 
significantly reduced the area of COX-1 and COX-2 
immunostaining (Figure 5B, C), and no treatment 
significantly increased COX expression, lending 
support to the safety of treatment. The observed 
effects were independent of fetal sex. 
SE175 does not alter human placental growth 
or function ex vivo 
To determine whether targeted delivery of SE175 
would detrimentally affect human trophoblast 
function, Rh-CNKG and SE175 were incubated with 
human placental explants. Rh-CNKG exhibited 
cell-penetrating properties, binding to and 
accumulating within the outer syncytiotrophoblast 
(STB) layer of first trimester explants within 30 
minutes (Figure 6A), and to a lesser extent in the STB 
of term placental explants (Figure 6B); minimal 
penetration of the peptide into the underlying villous 
stroma was observed in either tissue. These results 
suggested that SE175 would be delivered to the 
placental surface if administered via CNKG-loaded 
liposomes. To determine whether SE175 treatment 
altered any important parameters of placental growth 
or function, term explants were treated with SE175 for 
24 h; the nitric oxide donor SNAP was included as a 
positive control. SE175 treatment did not significantly 
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alter the rate of amino acid transport, as measured by 
Na+-dependent 14C meAIB uptake (Figure 6C), hCG 
secretion, a measure of trophoblast cell differentiation 
(Figure 6D), the basal rate of proliferation (Figure 6E) 
or apoptosis (Figure 6F).  
 
 
Figure 4: Targeted delivery of SE175 increases fetal weight and placental efficiency in eNOS-/- mice. eNOS-/- (N = dams, n = fetuses) were 
intravenously injected with 100 µL of PBS (N = 14, n = 113; closed black square), CNKGLRNK-decorated liposomes containing PBS (N = 9, n = 67; upward facing 
black triangle), CNKGLRNK-decorated liposomes containing SE175 (N = 10, n = 68; downward facing black triangle) or free SE175 (N = 8, n = 57; open black square). 
Data from PBS-treated C57BL/6J mice are shown for comparison (N = 17, n = 115; closed black circle). [A] Fetal weights, [B] curve fits to fetal weight distributions, 
[C] placental weights, [D] fetal:placental weight ratio (F:P), [E] spiral artery diameter (n = 3 placentas from N = 3 mice were assessed).  Data points represent 
individual fetuses, placentas or arteries; mean ± SEM. Horizontal red dashed line represents vehicle control mean. Means were compared using one-way ANOVA with 
Dunnett’s post hoc test. *P<0.05, **P<0.006, ****P<0.0001. 
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Figure 5. Targeted delivery of SE175 reduces expression of the oxidative stress markers 4-HNE, COX-1 and COX-2 in eNOS-/- mice 
Immunostaining of the mouse placental labyrinth with antibodies to [A – F] 4-HNE; [G – L] COX-1; [M – R] COX-2. [A, G, M] PBS-treated C57BL/6J mice, [B, 
H, N] PBS-treated eNOS-/- mice; [C, I, O] eNOS-/- mice treated with CNKGLRNK-decorated liposomes containing PBS (L-PBS); [D, J, P] eNOS-/- mice treated 
with CNKGLRNK-decorated liposomes containing SE175 (L-SE175); [E, K, Q] eNOS-/- mice treated with free SE175; [F, L, R] eNOS-/- mice, IgG control. Blue = 
hematoxylin; Brown = DAB; scale bars = 50 µm. n = 3 placentas from N = 4 mice were assessed; representative images are shown. [S-U] Quantitative assessment 
of DAB:Hematoxylin ratio of total area of [S] HNE; [T] COX-1; [U] COX-2. Mean ± SEM. Horizontal red dashed line represents vehicle control mean. Means were 
compared using a Kruskal Wallis test with Dunnett’s post hoc test. *P<0.05; **P<0.01. 
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Figure 6: SE175 does not alter human placental growth or function [A] First trimester and [B] term human placental explants were incubated with 
Rh-CNKGLRNK (0.27 µmol/L) for up to 3 h. Peptide binding and uptake were assessed by fluorescence microscopy; (n = 3). Representative images are shown. 
Rh-labelled peptides, red; DAPI (nuclei), blue. ST = syncytium; VS = villous stroma; scale bar = 50 µm. [C-F] Term placental explants were treated with DMSO 
(vehicle control), SE175 or the nitric oxide donor SNAP for 24h. [C] Na+-dependent [14C]MeAIB uptake at 30, 60 and 90 min; mean ±SEM; n = 6. [D] Percent 
control hCG secretion as measured by ELISA; mean, n = 6. [E] Percent of Ki67-positive (in-cycle) cells; mean, n = 5. [F] Percent of M30-positive (apoptotic) cells; 
mean, n = 5. 
 
Discussion 
Here we present evidence that the 
placental-specific homing peptide sequence 
CNKGLRNK acts as an efficient cell-penetrating 
peptide and can be conjugated to biocompatible 
liposomes. The resultant preparation selectively binds 
to the outer syncytiotrophoblast layer of human 
placenta ex vivo, and to the maternal uterine arteries 
and vasculature of the placental labyrinth in mice. We 
show that a novel vasodilator compound, the NO 
donor SE175, is able to induce vasodilation of mouse 
uterine arteries and human chorionic plate arteries ex 
vivo. We detected no adverse effect of SE175 on 
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several parameters of human placental growth and 
function and peptide-decorated liposomes 
encapsulating SE175 are well tolerated by pregnant 
mice. Finally, targeted delivery of SE175 to pregnant 
eNOS-/- mice, which exhibit dysregulated vascular 
function and FGR, enhances fetal growth such that the 
smallest fetuses are elevated above the tenth centile of 
weight, a commonly used clinical definition of growth 
restriction. Placental weight is decreased and 
placental efficiency is significantly enhanced. 
Furthermore, mean spiral artery diameter is 
significantly increased, and placental expression of 
the oxidative stress markers COX-1, COX-2 and HNE 
is significantly reduced, suggestive of enhanced 
uteroplacental perfusion. 
FGR is a significant cause of stillbirth, neonatal 
morbidity and mortality [1,2], as well as 
developmental programming, which increases the 
risk of chronic diseases in adulthood [43]. As 
management strategies are limited and there are 
currently no therapeutics licensed for use, it is of 
utmost importance to identify new approaches for the 
treatment of FGR in utero. A major barrier to drug 
development in obstetrics is the risk of side effects in 
mother or fetus. A strategy that has proven useful in 
limiting off-target side effects of chemotherapy has 
been the development of targeted drug delivery 
systems [10]. We have previously demonstrated the 
potential of peptide-conjugated liposomes as a means 
of selectively delivering a drug payload to the 
placenta, resulting in enhanced fetal growth in the 
absence of systemic side effects. We showed that 
targeted placental delivery of insulin-like growth 
factor-II (IGF-II) was more effective than systemically 
administered free IGF-II in improving fetal growth in 
the P0 mouse model of FGR [16]. That work used a 
previously identified tumour-homing sequence that 
exhibited high affinity for uteroplacental tissues. In 
the present study, we took a different approach, using 
phage screening to identify novel homing sequences 
that selectively target the maternofetal interface in 
mice. Multiple rounds of phage biopanning led to the 
identification of numerous sequences with specificity 
for the uteroplacental vasculature; of the individual 
sequences tested, NKGLRNK exhibited the high 
degree of specificity for this vascular bed, and was not 
observed in fetal tissues, so was selected for 
incorporation into our liposome formulation. 
Interestingly, when using these nanoparticles for 
SE175 delivery, we observed comparable results to 
King et al. (2016): targeted SE175 significantly 
increased mean fetal weight and appeared to be of 
most benefit to the smallest fetuses within each litter, 
yet the weight of the largest fetuses was not increased. 
This suggests that like targeted IGF-II [16], targeted 
SE175 acted preferentially on fetuses at most need of a 
growth stimulus, namely those in which growth 
restriction equated to a widely accepted clinical 
definition of FGR. We hypothesize that maternal 
and/or placental regulatory mechanisms exist to 
prevent overgrowth of healthy fetuses in response to 
external stimuli; thus, the beneficial effects of SE175 
were limited to the smallest placentas and fetuses 
within the litter. 
There is accumulating evidence in humans that 
impaired blood flow through the uteroplacental unit 
occurs in some cases of FGR [4], and that abnormal 
vascular anatomy [17,44] and impaired myometrial 
and chorionic plate vascular function contribute to the 
underlying pathophysiology [18-22]. In parallel, there 
has been increasing interest in the use of vasodilators 
such as sildenafil citrate [26-28], carbon monoxide 
[45-47] and hydrogen sulphide [48-50] as putative 
therapeutics in mice and humans. However, these 
compounds are not without side effects; maternal 
sildenafil citrate administration impaired fetal aortic 
vascular function, reduced fetal glucose tolerance and 
caused elevated blood pressure in adulthood in mice 
[27,31], and caused fetal cerebral blood overflow in 
the pregnant rabbits [51]. In mice, carbon monoxide 
exposure in pregnancy has been linked to increased 
resorptions [52], fetal skeletal variants [53], gross fetal 
malformations [52] and learning impairment in 
offspring [54]. Hydrogen sulphide is a mucous 
membrane and respiratory tract irritant and an 
inhibitor of the cytochrome c oxidase system that can 
cause anoxia. Thus, we sought to examine the 
therapeutic potential of another compound, the nitric 
oxide donor SE175 [55]. SE175 has a short half-life in 
vivo and therefore a short diffusion distance once 
released. As it spontaneously liberates NO following 
cleavage by cell-surface esterases, development of 
tolerance is much less likely than with traditional 
nitrate-based therapies [56]. Here we demonstrate 
that both free- and liposomally encapsulated SE175 
causes vasorelaxation of pre-constricted mouse 
wild-type and eNOS-/- uterine arteries and human 
chorionic plate arteries. Furthermore, SE175 did not 
detrimentally alter the basal rate of proliferation, 
apoptosis, differentiation or amino acid transport in 
human term placental explants, nor alter placental 
growth and function in mice, suggesting it may be a 
promising candidate for use in women. As NO has 
been implicated as a regulator of a number of 
important trophoblast functions including cell 
turnover, invasion and protection from apoptosis 
[57-59], this is a very positive outcome. 
In vivo, targeted delivery of SE175 significantly 
decreased placental expression of the oxidative stress 
marker 4-HNE, an unsaturated hydroxyalkenal that is 
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produced by lipid peroxidation in cells. Oxidative 
stress has previously been shown to induce 
upregulation of COX enzyme expression in the mouse 
placenta [37]; in our study, expression of COX-1 and 
COX-2 was also reduced by SE175. These findings 
imply that either SE175 significantly enhanced local 
blood flow to reduce oxidative stress, or that it 
exhibits additional antioxidant properties. Given that 
liposomally-encapsulated SE175 also increased mean 
spiral artery diameter, this provides more evidence 
for improved uteroplacental perfusion following 
administration of SE175. Suboptimal placental 
function is characterised by increased placental 
oxidative stress [60] which in turn can lead to vascular 
dysfunction [61], so this observation highlights 
another potential benefit of SE175.  
It has been hypothesised that the salicylate-like 
breakdown product of SE175 may act as an inhibitor 
of cyclooxygenase (COX) activity [55]. As COX-1 
expression is elevated in the placentas of women with 
pre-eclampsia [62], and COX inhibition improves fetal 
growth and attenuates late gestational hypertension 
in mice [63], we sought to examine whether SE175 
exerts beneficial effects on human placental growth 
and function that are additional to those associated 
with the NO donor SNAP, which does not inhibit 
COX. There was no significant difference between the 
effects of SNAP and SE175 on trophoblast turnover, 
amino acid uptake or hCG secretion in human term 
placental explants; thus, either SE175 did not reach a 
concentration high enough to inhibit COX activity, or 
COX inhibition had no effect on the parameters 
tested.  
Much of the previous work on targeted 
nanoparticles has focussed on delivery of 
chemotherapeutics to tumours; as such, the 
biocompatibility and safety of the nanocarriers has 
been considered of lesser importance, with any 
reduction in systemic side effects being regarded as 
advantageous. Moreover, as the primary aim is to 
eliminate the tumour cells, any tissue-specific 
cytotoxicity is viewed as an additional positive 
outcome. The evaluation of nanoparticle effects on the 
placenta and its vasculature requires a more rigorous 
approach to the detection of toxicity. Studies of 
nanoparticle biodistribution and fetoplacental toxicity 
in pregnancy have determined the effects of size, 
surface charge and composition on outcome 
(reviewed by [64]). The emerging picture indicates 
that the majority of the nanoparticles assessed, 
including quantum dots, silica, gold and iron oxide 
nanoparticles, exhibit significant placental transfer, 
fetal accumulation and cytotoxicity. Thus, liposomes 
represent an attractive option for nanoparticle- 
mediated placental drug targeting. The peptide- 
decorated liposomes used in this study did not cross 
the placenta, did not accumulate in fetal tissues and 
repeated administration did not cause any apparent 
fetal toxicity or physical deformities. In addition, 
treated dams did not display any signs of distress, 
and gross morphological analysis of maternal organs 
indicated no apparent abnormalities. Litter size and 
the number of resorptions were similar between 
treatment groups. However, since sequential 
measurements cannot be taken from the same animal 
with the methodologies used in this study, additional 
work is required to further understand nanoparticle 
absorption, distribution, metabolism and excretion, 
along with a detailed study of neonatal outcome. 
Development of novel therapeutics for use in 
pregnancy is an area that has historically proved 
difficult to translate from the bench to the clinic. 
However, there is now a precedent for this: sildenfil 
citrate [65] and melatonin [66] are undergoing clinical 
trials for treatment of fetal growth restriction [67], and 
a novel vascular endothelial growth factor (VEGF) 
adenoviral gene therapy, which significantly increases 
uterine blood flow and fetal growth in guinea pigs 
and sheep, is being tested in humans [68-71]. Thus, 
our novel system for selectively targeting the 
uteroplacental vasculature and identification of SE175 
as a safe and effective uteroplacental vasodilator 
holds much promise for the future. 
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